# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:APTO) with a Overweight and maintains $5 price ta...
HC Wainwright & Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:APTO) with a Buy and maintains $23 pri...
Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(...
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...
Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:APTO) with a Overweight and lowers the price targ...
SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (N...